Eli Lilly and Company has partnered with OpenAI to develop new antibiotics to combat antimicrobial resistance (AMR). The collaboration is part of Lilly’s commitment to the AMR Action Fund, which aims to provide patients with new antibiotics by 2030. OpenAI has also collaborated with other companies like Sanofi and Formation Bio to develop AI-powered software for drug development. Researchers like James Zou from Stanford University are optimistic about the role of generative AI in discovering new molecules for antibiotics. Academic research groups are increasingly using generative AI to synthesize new antibiotics, with recent studies showcasing the potential of AI in identifying antibiotic compounds that can combat drug-resistant bacteria. Felix Wong, lead author of a Nature study on AI-based drug discovery, believes that AI is a crucial tool in identifying novel molecules and drug targets. Overall, the partnership between Lilly and OpenAI represents an exciting development in the field of drug discovery and the fight against AMR.
Source link
Source link: https://cen.acs.org/policy/global-health/Lilly-partners-OpenAI-develop-novel/102/i20
Lilly collaborates with OpenAI to create innovative antibiotics #healthcare
